Клиномир в тестовом запуске. Кто с нами с первых дней, получит отметку «С первых дней» в профиле и первым увидит новые возможности сайта.

Зарегистрироваться
Идёт Россия

D4194R00027

A Multi-center, Non-interventional, Prospective Study of Durvalumab in Unresectable Locally Advanced NSCLC in Routine Clinical Practice in Russia

Номер протоколаD4194R00027
ФазаФаза не указана
Участников по плану — во всех странах исследования250
Сроки31.05.2022 — 30.11.2026
Начало: 31 мая 2022Окончание: 30 ноября 2026
Пройдено 99% планового срока

Постоянная ссылка: https://clinomir.ru/trials/nct/NCT05456867/

Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда

Простыми словами

Словарь терминов
  • Исследование идёт.
  • Возраст участников: от 18 лет. Остальные условия — в блоке «Кто может участвовать».
  • По плану участвуют 250 чел. во всех странах исследования.
  • Плановое окончание — 11.2026.

Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.

Кто может участвовать

Возрастот 18 лет
ПолЛюбой
Здоровые добровольцынет
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 1 · невключение: 12

Критерии включения

  • Patients are eligible to be included in the study only if all of the following inclusion criteria and none of the

Критерии невключения

  • apply:
  • Written informed consent obtained from the patient prior to performing any protocol-related procedures
  • Age ≥18 years at time of study entry
  • Patients must have histologically or cytologically documented diagnosis of NSCLC with a locally advanced, or locally recurrent, unresectable (stage III) disease (according to American Joint Committee on Cancer \[AJCC\] lung cancer edition 8)
  • Patients must have completed a platinum-based chemotherapy with radiation therapy (concurrent or sequential) without evidence of disease progression
  • Patients must have been treated with at least one dose of durvalumab
  • Exclusion Criteria:
  • Any subject who meets any of the following criteria will not qualify for entry into the study:
  • Absence or missing of written informed consent form
  • Patients treated with durvalumab in clinical studies
  • Absence of essential data to obtain all necessary information
  • Confirmation that the subject was already included in this study before

Источник: ClinicalTrials.gov, NCT05456867 · запись обновлена в реестре 17 марта 2026.

Дизайн и результаты

ДизайнНаблюдательное
Участников по плану (все страны)250
Результатыбудут после окончания
Что измеряют — первичные конечные точки (10)
  • Safety of durvalumab in patients with unresectable locally advanced NSCLC without progression after CRT in routine practice of the Russian Federation. — Up to 54 month
  • Number of any treatment (durvalumab) related AEs by physician diagnosis within all treatment period plus 3 months after durvalumab discontinuation. — Up to 54 month
  • Number of any treatment (durvalumab) related AEs by physician diagnosis within all treatment period plus 3 months after durvalumab discontinuation separately for fix dose (1500mg every 4 weeks) and 10mg/kg every 2 weeks dosage. — Up to 54 month
  • Number of irAEs — Up to 54 month
  • Number of SAEs — Up to 54 month
  • Number of grade 3-4 AEs — Up to 54 month
  • Number of post discontinuation irAEs — Up to 54 month
  • Number of AESIs — Up to 54 month
  • Number of AEs which lead to discontinuation — Up to 54 month
  • Time to pneumonitis [median, months] — Up to 54 month

Цель исследования

Durvalumab was approved in the Russian Federation for use after both concurrent and subsequent CRT until disease progression. Currently, there is no real-world data regarding the safety and real world effectiveness of durvalumab in this indication. Moreover, generation data on the safety and real world effectiveness of durvalumab after concurrent chemo-radiation therapy (cCRT) and subsequent chemo-radiation therapy (sCRT) in routine practice in the Russian Federation will be of high relevance.

The other important question that needs to be addressed is the duration of treatment with durvalumab and its' influence on the relevant outcomes. According to the Russian label, it is possible to continue treatment with durvalumab until disease progression, although current data from the PACIFIC trial provide the results on 12 months duration of durvalumab treatment. The real-world data about the duration of treatment with durvalumab in the Russian population and its' influence on various outcomes would be very important.

Among other goals, the current study is aimed to analyze factors influencing the effectiveness of durvalumab therapy in the real-world setting (e.g. duration of treatment, delays in the start of treatment with durvalumab after CRT over, early discontinuation due to any factors including AEs, etc.). The study also aims to elucidate treatment approaches after discontinuation from durvalumab (post-progression outcomes and treatment in case of discontinuation due to AEs). This study will support the understanding of described factors and will take and an attempt to optimize the treatment process to improve outcomes for patients

Где проходит

0 центров

Центры в реестре не указаны.

Откуда эта информация

  • ClinicalTrials.gov (U.S. National Library of Medicine) · NCT05456867 Официальный реестр (США) · загружено 9 ноября 2026
    Номер протокола, название, цель, статус, сроки, число участников, спонсор

Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.

Изменения не сохранены

На этой странице есть несохранённые изменения. Если уйти со страницы, они пропадут.